Sign In to Request a Protocol
Sign In to Request a Protocol

BPC-157 + TB-500 (10 mg Blend) Vitality Labs Protocol

  • Table of Contents

BPC-157 + TB-500 Research Information Chart

The BPC-157 + TB-500 peptide blend is dosed at 600 mcg–800 mcg daily via subcutaneous injection in educational protocols. A 10 mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

  • Research Preparation Information: Add 3.0 mL bacteriostatic water → 3.33 mg/mL total concentration (1.67 mg/mL of each peptide).
  • Typical daily range: 600–1000 mcg total blend once daily (provides 300–500 mcg of each peptide).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg total blend on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after Research Preparation Information, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

This blend combines two well-studied regenerative peptides: BPC-157 (Body Protection Compound-157), a pentadecapeptide derived from human gastric juice with cytoprotective and wound-healing properties[1][2], and TB-500 (Thymosin Beta-4 fragment), a 43-amino-acid peptide involved in tissue repair, cell migration, and angiogenesis[3][4]. This educational protocol presents a <b>once-daily subcutaneous</b> approach using a practical dilution for clear insulin-syringe measurements.

  • Research Preparation Information

Educational guide for Research Preparation Information and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Route: Subcutaneous injection, once daily[5][6]. This blend contains equal amounts of BPC-157 and TB-500 (5 mg each); every dose drawn provides a 1:1 ratio of both peptides.
Phase / WeekDaily Dose (Total Blend) Each Peptide (mcg)Units (mL)
Weeks 1–2 (Initial)600 mcg300 mcg BPC + 300 mcg TB-50018 units (0.18 mL)
Weeks 3–4 (Loading)800 mcg400 mcg BPC + 400 mcg TB-50024 units (0.24 mL)
Weeks 5–8 (Maintenance)600 mcg300 mcg BPC + 300 mcg TB-50018 units (0.18 mL)
Frequency: Inject once daily subcutaneously. This schedule uses 3.0 mL dilution to keep per-injection volumes ≥18 units for accurate measurement. Rotate injection sites systematically[7].

Research Preparation Information

  • 1 . Draw 3.0 mLbacteriostatic water with a sterile syringe.
  • 2 . Inject slowly down the vial wall; avoid foaming or vigorous shaking.
  • 3 . Gently swirl/roll until fully dissolved (do not shake).
  • 4 . Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Advanced / Aggressive Approach (Acute Injury Support)

For acute tissue injuries, some protocols suggest a higher initial loading phase[8][9]. This approach uses higher daily doses during the first 4 weeks before tapering to maintenance. Use with caution; robust human dose-finding data remain limited.

Phase / WeekDaily Dose (Total Blend)Each Peptide (mcg)Units (mL)
Weeks 1–2 (Aggressive Load)1000 mcg500 mcg BPC + 500 mcg TB-50030 units (0.30 mL)
Weeks 3–4 (High Load)800 mcg400 mcg BPC + 400 mcg TB-50024 units (0.24 mL)
Weeks 5–8 (Maintenance)600 mcg300 mcg BPC + 300 mcg TB-50018 units (0.18 mL)

Note: A small human case series combining BPC-157 and TB-500 for joint injuries reported improved outcomes at higher combined doses (4 mg BPC + 6 mg TB-500 intra-articular) compared to lower doses[8]. However, systemic subcutaneous protocols typically use the ranges above. Treatment duration is generally limited to 8–12 weeks before cycling off to evaluate response[9].

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Research Requirements

Plan based on an 8–16 week daily protocol with phased dosing (averaging ~700 mcg/day over the cycle).

  • Peptide Vials (BPC-157 + TB-500, 10 mg blend each):
  • 8 weeks ≈ 4 vials
  • 12 weeks ≈ 6 vials
  • 16 weeks ≈ 8 vials
  • Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for Research Information .
  • 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
  • Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support tissue repair, wound healing, and recovery from musculoskeletal injuries[1][3].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if needed).
  • Dose Range: 600–1000 mcg total blend daily (300–500 mcg of each peptide).
  • Research Preparation Information: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
  • Research Applications

Suggested daily phased approach.

  • Start: 600 mcg total daily (300 mcg each peptide) for Weeks 1–2.
  • Loading: Increase to 800 mcg daily for Weeks 3–4.
  • Maintenance: Return to 600 mcg daily for Weeks 5–8+.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Material Handling Considerations

Proper storage preserves peptide quality and stability.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4–6 weeks; avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes

Practical considerations for consistency and safety.

  • Both peptides are not approved for routine human use (sold for research purposes) and are banned in competitive sports[10].
  • Use new sterile insulin syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[7].
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • How This Works

BPC-157 is a stable pentadecapeptide that promotes angiogenesis, modulates nitric oxide pathways, and demonstrates broad cytoprotective effects across gastrointestinal, musculoskeletal, and neurological tissues in preclinical models[1][2]. It has shown activity at very low doses (nanogram to microgram per kilogram) without demonstrable toxicity in animal studies[11].

 

TB-500 (Thymosin Beta-4) is an actin-sequestering peptide that promotes cell migration, wound healing, and anti-inflammatory responses[3][4]. It is well-tolerated in animal and early clinical studies, even at multi-milligram doses[12].

 

Combining these peptides may provide complementary mechanisms for tissue repair: BPC-157 for its trophic and anti-inflammatory effects, and TB-500 for enhanced cell migration and angiogenesis[8].

  • Potential Benefits & Side Effects

Observations from preclinical and limited clinical literature.

  • May support accelerated healing of tendons, ligaments, muscles, and soft tissue injuries[1][5].
  • Preclinical evidence suggests gastroprotective and anti-inflammatory properties for BPC-157[2].
  • TB-500 promotes wound healing and may reduce scarring through enhanced cell migration[3].
  • Both peptides are generally well tolerated; occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.
  • No significant toxicity has been documented up to high doses in animal studies[11][12].
  • Lifestyle Factors

Complementary strategies for optimal recovery outcomes.

  • Prioritize adequate protein intake (1.6–2.2 g/kg body weight) to support tissue repair.
  • Follow appropriate rehabilitation protocols for any injuries being addressed.
  • Ensure adequate sleep (7–9 hours) to optimize recovery and tissue regeneration.
  • Manage inflammation through balanced nutrition and stress reduction techniques.
  • Scientific Research Information

General subcutaneous guidance from clinical best-practice resources[6][7].

  • Clean the vial stopper and skin with alcohol; allow to dry completely.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[13].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[13].
  • Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms, flank) to avoid lipohypertrophy[7].
  • Apply gentle pressure post-injection; do not rub the site.
  • Recommended Source
We recommend Vitality Labs Peptides for high-purity BPC-157 + TB-500 (10 mg blend).

Why Vitality Labs Peptides?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Contact on Telegram
  • Important Note

This content is for educational purposes only and is not medical advice.

  • References

Explore related research Research Preparation Information protocols and background reading for BPC-157 + TB-500.

PubMed

— Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
More Info

Current Pharmaceutical Design (PubMed)

— Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract
More Info

PMC

— Utilizing developmentally essential secreted peptides such as Thymosin Beta-4 for regenerative therapies
More Info

Annals of the New York Academy of Sciences (PubMed)

— Thymosin beta 4 and wound healing: new ideas
More Info

PMC

— Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review
More Info

Johns Hopkins Arthritis Center

— How to give a subcutaneous injection
More Info

PMC

— Subcutaneous drug delivery review: pharmacologic considerations
More Info

ASIPP / Alternative Therapies in Health and Medicine

— Intra-articular injection of BPC-157 for multiple types of knee pain
More Info

A4M

— Thymosin Beta-4 professional monograph
More Info

PubMed

— Detection of thymosin beta-4 and related peptides in sport drug testing
More Info

Journal of Physiology and Pharmacology (PubMed)

— BPC-157 activity at very low doses without toxicity in animal studies
More Info

Expert Opinion on Biological Therapy (PubMed)

— Thymosin beta-4 and its role in wound healing
More Info

CDC

— Vaccine administration: subcutaneous route (angle/site; no aspiration)
More Info

NCBI Bookshelf

— Best practices for injection (asepsis, preparation, and administration)
More Info

Contact on Telegram Peptides

BPC-157 + TB-500 (10 mg blend) product page (quality and batch documentation)
More Info